503A vs 503B: What Is Actually in the Vial

Two schemes, one word

"Compounded" covers two legally distinct arrangements, and the difference between them is the single most useful thing a reader can know about an injectable that did not come from a manufacturer.

Section 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician¹.

Section 503B created outsourcing facilities, a category established in 2013 by the Drug Quality and Security Act. These register with FDA, are inspected by FDA on a risk-based schedule, and are subject to increased quality standards¹.

The difference that matters most

FDA states it plainly: drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements, and by contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A, are not¹.

CGMP is the framework that covers process validation, environmental monitoring, sterility assurance, documentation and release testing. Its absence under 503A is not a loophole — it is the design. 503A contemplates a pharmacist making a preparation for one identified patient, not a production run.

Oversight follows the same split. State boards of pharmacy have primary day-to-day responsibility for state-licensed pharmacies that are not registered as outsourcing facilities, with FDA conducting surveillance and for-cause inspections. Facilities registered under 503B are primarily overseen and inspected by FDA¹.

What each may legally start from

This is where unapproved peptides run into a wall, and it is worth reading carefully.

Under 503A, a compounder may use a bulk drug substance that complies with an applicable United States Pharmacopeia or National Formulary monograph if one exists, together with the USP chapter on pharmacy compounding; or that is a component of an FDA-approved drug product if no such monograph exists; or that appears on FDA's 503A bulks list, if there is no monograph and it is not a component of an approved product².

Under 503B, an outsourcing facility may not compound a drug product using a bulk drug substance unless that substance appears on the 503B bulks list — the list of substances for which FDA has determined there is a clinical need — or the compounded drug product appears on FDA's drug shortage list at the time of compounding, distribution and dispensing³.

Both schemes carry the same two additional requirements, and they are the ones people forget. Bulk drug substances must be accompanied by a valid certificate of analysis, and must have been manufactured by an establishment registered with FDA under section 510 of the FD&C Act², and the same conditions apply on the 503B side³.

That second requirement is doing quiet work. A certificate from an unregistered manufacturer does not satisfy it, whatever the certificate says — a distinction taken apart in what a certificate of analysis proves.

The interim categories

While FDA evaluates nominated substances, it operates an interim policy sorting them into three categories: substances that may be eligible and were nominated with sufficient information (category 1), substances nominated with sufficient information but for which FDA has identified significant safety risks (category 2), and substances nominated with insufficient information for FDA to evaluate (category 3)³.

Most peptides sold outside the approved-drug system are not in category 1. Where they sit, and the important detail about withdrawn nominations, is covered in what "research chemical" actually means.

The inspection record, measured

503B is the stronger tier. It is worth knowing how strong in practice.

A mixed-methods study of FDA registration and inspection data examined 48 outsourcing facilities registered between 1 January 2020 and 30 April 2025. Of those 48, 11 (22.9%) had been inspected, with an average delay of 2.2 years from registration to inspection⁴.

Each of the 11 inspected facilities had at least two significant objectionable findings, with a mean of 6.2 findings and a standard deviation of 3.2⁴.

Thematic analysis of 68 findings identified five domains of deficiency — quality control, personnel training, documentation, process validation and product labelling — with frequent issues including inadequate sterility testing, poor environmental controls, unvalidated production processes and deficient recordkeeping⁴.

What the public registry shows

FDA publishes the list of registered outsourcing facilities and refreshes it weekly. The version published 4 August 2026 lists 96 facilities, with columns for initial registration date, most recent registration, last inspection, whether a Form 483 was issued, whether a recall was conducted, and the action taken based on the last inspection⁵.

Counting the rows on that version: 37 of the 96 record "Not yet inspected" in the last-inspection column, and 5 record a warning letter in the action column⁵.

Anyone can reproduce that count in about a minute, and it is a better guide to what "FDA-registered outsourcing facility" means than the phrase itself. Registration is a filing. Inspection is an event that may not have happened yet.

Where this leaves an unapproved peptide

Neither scheme is a route by which a substance that is not on the relevant list becomes legally compoundable. FDA has stated, for example, that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs⁶.

So the tiering for a reader looks like this.

An FDA-approved product — identity, purity, sterility and stability were verified before marketing.

A 503B compounded product — made under CGMP by a facility FDA may or may not have inspected yet, from a substance that must be on the 503B bulks list or cover a shortage.

A 503A compounded preparation — made for an identified patient, not under CGMP, overseen primarily by a state board.

Anything else — outside all three, with no scheme attaching and no approved article to compare it to.

Three questions worth asking

Which section was this made under? A 503B facility appears by name in FDA's public registry; a 503A pharmacy does not.

If 503B, when was the facility last inspected, and what does the action column say? Both fields are in the same public table.

What was the starting material, and is it on the list that scheme requires? If the answer is a substance with no monograph, no approved product containing it, and no place on either bulks list, then the vial is outside the framework entirely.